No quarterly revenue total was found in Acrivon Therapeutics, Inc.'s SEC filings.
Acrivon Therapeutics, Inc. (ACRV) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$14.9 million. As of Jun 30, 2026 it held $90.0 million in cash and investments and $2.1 million in total debt.
Revenue
—
Net income
$-17.96M
+14.5% vs year-ago quarter
Operating cash flow
$-14.86M
+10.5% vs year-ago quarter
Free cash flow
$-14.95M
+12.6% vs year-ago quarter
EPS
$-0.43
+21.8% vs year-ago quarter
Dividend per share
None
Shares outstanding
42.85M
+36.2% vs year-ago quarter
Net cash
$87.84M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ACRV (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Watertown, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1781174
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$18.7M | -$19.9M | -$20.1M | -$19.7M | -$22.6M |
| Net income | -$18.0M | -$19.0M | -$19.0M | -$18.2M | -$21.0M |
| Diluted EPS | -$0.43 | -$0.49 | -$0.49 | -$0.47 | -$0.55 |
| Operating cash flow | -$14.9M | -$20.5M | -$15.2M | -$12.3M | -$16.6M |
| Free cash flow | -$14.9M | -$20.6M | -$15.5M | -$13.2M | -$17.1M |
| Total assets | $99.1M | $107.8M | $129.7M | $145.3M | $158.6M |
| Total liabilities | $12.4M | $12.3M | $17.2M | $16.7M | $15.5M |
| Stockholders' equity | $86.7M | $95.5M | $112.5M | $128.6M | $143.0M |
| Cash and investments | $90.0M | $97.7M | $118.6M | $134.4M | $147.6M |
| Total debt | $2.1M | $2.4M | $2.7M | $3.0M | $3.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Aug 12, 2026 | Aug 12, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 17, 2026 | Jun 17, 2026 |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 13, 2026 | May 13, 2026 |
| ARS | Annual report to shareholders | Apr 30, 2026 | Dec 31, 2025 |
All 346 Acrivon Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.